Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer

Figures & data

Table 1 Summary of miRNAs and related mRNA targets

ID	Accession	Previous IDs	mRNA targets
miR-146a-5p	MIMAT0000449	hsa-miR-146; hsa-miR-146a	NLRP3
miR-106a-5p	MIMAT0000103	hsa-miR-106a	NLRP3
miR-17-5p	MIMAT0000070	hsa-miR-17-5p; hsa-miR-17	NLRP3*,^Citation38
miR-223-3p	MIMAT0000280	hsa-miR-223	NLRP3*,^Citation35
miR-141-3p	MIMAT0000432	hsa-miR-141	NLRP3; NLRP4
miR-19a-3p	MIMAT0000073	hsa-miR-19a	NLRP9
miR-145-5p	MIMAT0000437	hsa-miR-145	NAIP*,^Citation45
miR-185-5p	MIMAT0000455	hsa-miR-185	NAIP

Note:

* Validated interactions.

Figure 1 Expression levels expressed as −ΔCt (median with range and interquartile range) of selected miRNAs.

Notes: *P<0.05; **P<0.01.

Table 2 Hematological and clinical parameters of enrolled subjects

Variables	Group I (BC, n=46)	Group II (CTR1, n=28)	Group III (CTR0, n=31)	P-value I vs II	P-value I vs III	P-value II vs III
Degree of bladder wall infiltration
Ta	26
T1	14
T2	6
Tumor grade
Low	18
High	28
Risk of recurrence and progression
Low	17
High	29
Age (years)
Median	65	62	64	0.45	0.68	0.7
Range	45–84	63–81	47–82
SD	9.46	10.2	12.57
Gender
Male	37	24	25	0.33	0.9	0.27
Female	9	4	6
${\text{Leukocytes}}^{(\times {10}^3/\text{mmc})}$
Median	8.15	7.02	7.64	0.36	0.49	0.87
Range	2.21–18.99	5.06–10.74	3.55–12.28
SD	3.47	2.38	2.77
${\text{Neutrophils}}^{(\times {10}^3/\text{mmc})}$
Median	4.85	4.61	4.28	0.68	0.79	0.48
Range	1.04–12.59	2.49–6.3	1.82–9.02
SD	2.15	1.78	2.49
${\text{Lymphocytes}}^{(\times {10}^3/\text{mmc})}$
Median	2.35	1.52	1.68	0.16	0.13	1.00
Range	0.97–15.19	0.6–4.05	0.56–3.33
SD	2.35	1.07	1.12
${\text{Monocytes}}^{(\times {10}^3/\text{mmc})}$
Median	0.545	0.57	0.555	0.86	0.61	0.46
Range	0.25–1.15	0.14–1.33	0.31–1.71
SD	0.221	0.229	0.428

Abbreviations: BC, patients with bladder cancer; CTR1, subjects with bladder inflammation; CTR0, healthy controls; SD, standard deviation; mmc, cubic milliliter.

Figure 2 Expression levels expressed as −ΔCt (median with range and interquartile range) of selected miRNAs.

Notes: Comparisons were made according to tumor stage. *P<0.05.

Figure 3 Expression levels expressed as −ΔCt (median with range and interquartile range) of selected miRNAs.

Notes: Comparisons were made according to histological grade. *P<0.05.
Abbreviations: HG, high-grade; LG, low-grade.

Figure 4 Expression levels expressed as −ΔCt (median with range and interquartile range) of selected miRNAs.

Notes: Comparisons were made according to risk of recurrence and progression. *P<0.05.
Abbreviations: HR, high-risk; LR, low-risk.

Figure 5 Expression levels expressed as −ΔCt (median with range and interquartile range) of selected miRNAs.

Note: *P<0.05.
Abbreviations: NMI-HG, non-muscle invasive high-grade; NMI-LG, non-muscle invasive low-grade.

Table 3 Univariate and multivariate logistic regression analyses of variables predicting the outcome of disease

Logistic regression analysis	microRNA ID	P-value	(%) SN	(%) accuracy
HG vs LG BC	miR-17-5p	0.045	76.92	57.14
HR vs LR BC	miR-17-5p	0.028	81.48	61.9
	miR-19a-3p	0.049	82.14	60.47
NMI-LG vs NMI-HG	miR-17-5p	0.04	70	63.89
BC	miR-17-5p + miR-106a-5p + miR-19a-3p	0.017	76.92	80.77

Abbreviations: BC, bladder cancer; HG, high-grade; HR, high-risk; LG, low-grade; LR, low-risk; NMI-HG, non-muscle invasive high-grade; NMI-LG, non-muscle invasive low-grade; SN, sensitivity.

LernerAGUptonJPPraveenPVIRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stressCell Metab201216225026422883233

 PubMed Web of Science ®Google Scholar

HaneklausMGerlicMO’NeillLAMastersSLmiR-223: infection, inflammation and cancerJ Intern Med2013274321522623772809

 PubMed Web of Science ®Google Scholar

XuXWuXJiangQDownregulation of microRNA-1 and microRNA-145 contributes synergistically to the development of colon cancerInt J Mol Med20153661630163826459459

 PubMed Web of Science ®Google Scholar